Paul Barton is Honorary Senior Research Fellow at the National Heart and Lung Institute working in the Cardiovascular Genetics and Genomics Group.
He undertook a PhD in human genetics at the University of London followed by postdoctoral training at the Pasteur Institute in Paris under the direction of Dr Margaret Buckingham and supported by fellowships from the Muscular Dystrophy Association of America (MDA), the European Molecular Biology Organization (EMBO) and later, as a tenured scientist of the French Institut National de la Santé et de la Recherche Médicale (INSERM).
In 1989 he joined Professor Sir Magdi Yacoub at the newly formed National Heart and Lung Institute (NHLI) in order to investigate molecular and cellular mechanisms of cardiac development and disease supported by a 10 year Senior Research Fellowship from the British Heart Foundation. He later also served as Assistant Director of Research to the Magdi Yacoub Institute.
In 2011 he joined Professor Stuart Cook's Genetics and Genomics Group (cvgenetics.org) to investigate the molecular basis of inherited cardiac conditions. He is an Honorary Senior Research Fellow of Imperial College and acts as Research Manager for the Cardiovascular Genetics and Genomics Group.
Dr Barton has published over 160 research papers and elected Fellowships from the European Society of Cardiology (FESC) and the American Heart Association (FAHA).
et al., 2018, CardioClassifier: disease- and gene-specific computational decision support for clinical genome interpretation, Genetics in Medicine, Vol:20, ISSN:1098-3600, Pages:1246-1254
et al., 2017, Natural genetic variation of the cardiac transcriptome in non-diseased donors and patients with dilated cardiomyopathy, Genome Biology, Vol:18, ISSN:1474-7596
et al., 2017, Using high-resolution variant frequencies to empower clinical genome interpretation, Genetics in Medicine, Vol:19, ISSN:1530-0366, Pages:1151-1158
et al., 2017, Truncating variants in titin independently predict early arrhythmias in patients with dilated cardiomyopathy, Journal of the American College of Cardiology, Vol:69, ISSN:1558-3597, Pages:2466-2468
et al., 2017, Defining the genetic architecture ofhypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genes, European Heart Journal, Vol:38, ISSN:1522-9645, Pages:3461-3468
et al., 2016, Titin truncating variants affect heart function in disease cohorts and the general population, Nature Genetics, Vol:49, ISSN:1546-1718, Pages:46-53
et al., 2016, Recovery of cardiac function in cardiomyopathy due to titin truncation, Jama Cardiology, Vol:1, ISSN:2380-6583, Pages:234-235
et al., 2015, Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease., Sci Transl Med, Vol:7
et al., 2014, RNA-binding protein RBM20 represses splicing to orchestrate cardiac pre-rnRNA processing, Journal of Clinical Investigation, Vol:124, ISSN:0021-9738, Pages:3419-3430
et al., 2012, Truncations of Titin Causing DilatedCardiomyopathy, New England Journal of Medicine, Vol:366, Pages:619-628
et al., 2011, Endonuclease G is a novel determinant of cardiac hypertrophy and mitochondrial function, Nature, Vol:478, Pages:114-118
et al., 2011, Calcineurin splicing variant calcineurin Aβ1 improves cardiac function after myocardial infarction without inducing hypertrophy., Circulation, Vol:123, Pages:2838-2847